Illimis Therapeutics Funding: $63M Raised, Series B (2025)
Illimis Therapeutics is based in Seoul, South Korea. It has raised $63M in total funding. Latest round: Series B.
Illimis Therapeutics funding overview
Illimis Therapeutics is based in Seoul, South Korea. Illimis Therapeutics has raised $63M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in July 2025. The round record for Illimis Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include /DSC Investment/, Woori Venture Partners, Korea Development Bank, Hana Ventures, Aju IB Investment, IMM Investment and 12 others. 18 distinct backers are named across the disclosed rounds.
Illimis Therapeutics at a glance
Total raised
$63M
Latest round
Series B
Latest round date
July 2025
Headquarters
Seoul, South Korea
Notable investors
/DSC Investment/, Woori Venture Partners, Korea Development Bank, Hana Ventures, Aju IB Investment, IMM Investment, LB Investment, GS Ventures
Frequently asked about Illimis Therapeutics funding
How much has Illimis Therapeutics raised?
Illimis Therapeutics has raised $63M in total disclosed funding across the rounds on record.
Who has invested in Illimis Therapeutics?
/DSC Investment/, Woori Venture Partners, Korea Development Bank, Hana Ventures, Aju IB Investment, IMM Investment are named among the investors backing Illimis Therapeutics.
What was the latest Illimis Therapeutics funding round?
The most recent disclosed round is a Series B, announced in July 2025.
Where is Illimis Therapeutics based?
Illimis Therapeutics is based in Seoul, South Korea.
When did Illimis Therapeutics last raise?
The last disclosed Illimis Therapeutics round closed in July 2025 at Series B.
Round data for Illimis Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Seoul and backer lists below.
